tbuckley/cabot-search huggingface dataset:
Late-breaking abstract: Factors related to apnea in bariatric surgery patients using home sleep study
Authors: Luciano Grohs, Leticia Simonaggio
Journal: European Respiratory Journal (2014)

INTRODUCTION: The Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a risk factor for bariatric surgery. There aren´t clear risk factors to identify subpopulations at risk.

OBJECTIVES: Correlate clinical data and OSAHS in candidates for obesity surgery, using home sleep study.

METHODS: 53 sequential candidates for obesity surgery (BMI> 33), without diagnosis of OSAHS. It was recorded: Mallampati score (MS), neck circumference (NC), chin-sternum distance (CSD) and apnea and hypopnea index (AHI - measured by ApneaLink Plus ®). The apnea, as AHI, was classified as: absent (  30).

RESULTS: 43 women (81%) and 10 males (19%), with medium age of 38 years. Apnea was founded in 31 (58%) patients: mild in 17 (32%), moderate in 8 (19%) and severe in 6 (11%). The greater AHI was 115, and 4 had an AHI > 50. Of the 6 patients with severe apnea, 5 (83.33%) were male. In moderate apnea, 6 (75%) were female and in mild, 16 (94%). In severe apnea, the lowest BMI was 44. At moderate apnea, 80% were classified in grade III (BMI> 40). For MS, of the 44 patients with MS III or IV, 30 (68%) had apnea; , 4 (25%) of 20 patients with MS IV had severe sleep apnea and 6 (30%) had no apnea. For NC, 100% of patients with severe apnea had CC> 40, whereas only 41% of patients with mild apnea had this feature. The CSD had no correlation with AHI. The NC/CSD ratio ≥2.5 identified 77% (17/25) of OSAHS patients and 71% (10/14) of patients with moderate OSAHS.

CONCLUSIONS: Positive correlation with male gender and BMI> 44 was found. NC> 40 and the NC/CSD ratio > 2.5 ratio was associated with moderate or severe OSAHS. The portable monitoring was a reliable tool for this screening.
LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012
Authors: Y-J. Bang, H.C. Chung, V. Shankaran, R. Geva, D. Catenacci, S. Gupta, J.P. Eder, R. Berger, K. Emancipator, K. Pathiraja, T. McClanahan, M. Ayers, J. Lunceford, J. Cheng, M. Koshiji, K. Muro
Journal: Annals of Oncology (2015)
Abstract 17221: Incidence of Pacemaker-Detected Atrial Tachyarrhythmias in Elderly Patients with Hypertension and a History of Stroke or Transient Ischemic Attack
Authors: Jeff S Healey, Carlos A Morillo, Carsten W Israel, Isabelle C van Gelder, Michael R Gold, Alessandro Capucci, Mark Carlson, CP Lau, Stefan H Hohnloser, Stuart J Connolly
Journal: Circulation (2012)

Background: Undiagnosed atrial fibrillation (AF) is believed to be an important cause of cryptogenic stroke. A dual-chamber pacemaker is the most sensitive method for diagnosing atrial fibrillation...
Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
Authors: H Kunitoh, K Watanabe
Journal: Journal of Clinical Oncology (1994)

PURPOSE The primary objective of this study was to determine the pharmacodynamics of prolonged administration of low-dose etoposide by continuous infusion (CI). We investigated the hypothesis that maintenance of an etoposide concentration of 1 microgram/mL would be cytotoxic in non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Thirty patients with advanced NSCLC without prior chemotherapy or radiotherapy were treated with etoposide at 20, 25, or 30 mg/m2/d infused continuously for 14 days (336 hours), following a 10-mg/m2 bolus. They also received cisplatin 30 mg/m2 on chemotherapy days 1, 2, and 3. Plasma concentrations of etoposide were measured by high-performance liquid chromatography at 0, 2, 4, 24, 48, 120, 336, and 342 hours after initiation of CI etoposide. RESULTS The maximum-tolerated dose (MTD) of etoposide was 25 mg/m2/d with leukocytopenia as the dose-limiting toxicity. Plasma concentrations of etoposide at steady-state (Css) showed approximately twofold interpatient variability at each dose level, and were greater than 1 microgram/mL in most patients at higher dose levels. The severity of neutropenia was dependent on performance status (PS), age, and the Css of etoposide. The overall response rate for the 29 assessable cases was 28%. Five of 11 patients with a Css greater than 1.2 micrograms/mL responded to the therapy, whereas only one of 10 patients with a Css less than 1 microgram/mL responded. CONCLUSION With long-term CI of etoposide, a Css greater than 1 or 1.2 micrograms/mL appeared necessary, but not sufficient, to achieve a major response against NSCLC.
Gallbladder complications following resection of stomach for peptic ulcer
Authors: Clh. Majoor
Journal: BMJ (1947)

Abnormal conditions in the upper abdomen which may occur after resection of the stomach for peptic ulcer may be considered under several heads. A detailed investigation into the occurrence and frequency of gastro-jejunal ulcers would be outside the scope of this paper. Occasionally, during the past five years, we have observed severe haemor rhage following gastric resection, but on no occasion was there demonstrable radiological evidence of ulcer. It was noted that the patients rarely complained of pain. Symp toms arising from internal strangulation of the small intes tine by abnormal hernial rings are less frequent (for literature, see Suren, 1941). Of common occurrence are less serious complaints, often of a temporary nature, as observed by Wangensteen (1944). He did not encounter serious disorders or anastomotic ulcers. Poor appetite and a feeling of satiety are common, especially after partaking of liquid food. It would be incorrect to ascribe these phenomena to over-filling of a stomach of reduced capacity; for most radiologists are acquainted with the rapid emptying which follows resection. A reasonable presumption would be that the liquid either fills the afferent loop of the anastomosis or interferes with the flow of pancreatic biliary juices from that loop. Symptoms may conceivably arise in this manner, and they can be anticipated and prevented by advising the patients to eat dry food. It is an outstanding fact that porridge and milk no longer agree with patients who, prior to operation, had lived almost entirely on that diet. Frequently there is an aversion to fatty foods. Finally, some patients are troubled in the early post-operative period by regurgitatidn of bilious fluid. It is inferred from these findings that the downward flow of bile is impeded in resections of the Billroth II type. In many instances the resulting compli cations are slight and of a temporary nature. They may, however, be serious. Stolte (1942) carefully observed 333 cases of ulcer in the Department of Medicine of the  Onze Lieve Vrouwe Hospital at Amsterdam. Of these 333 patients 83 had previously undergone gastric resection and 26 had had gastro-enterostomy. Stolte found that gastro-jejunal ulcer was a complication in eight of those resected and in ten of those with gastro-enterostomy. Further, 22 patients after resection and four after gastro-enterostomy continued to have symptoms; but in no case could gastro-jejunal ulcer be demonstrated with certainty. The number, of patients with abdominal symptoms after operation on the stomach is remarkably large in this series. Their complaints were serious enough to warrant their admission to the medical clinic after they had been operated upon. We are greatly impressed with the fact that in Stolte's series severe unaccountable symptoms following stomach
A Multicenter Prospective Study on the Risk of Acquiring Liver Disease in Anti–Hepatitis C Virus Negative Patients Affected From Homozygous β-Thalassemia
Authors: Daniele Prati, Alberto Zanella, Elena Farma, Claudia De Mattei, Patrizia Bosoni, Manuela Zappa, Alessandra Picone, Fulvio Mozzi, Paolo Rebulla, Maria Domenica Cappellini, Jean-Pierre Allain, Girolamo Sirchia
Journal: Blood (1998)
The clinical relevance of p53 isoforms modifying the effects of p53 mutation on survival from breast cancer
Authors: A. Thompson, N. Patten, A. Diot, S. C. Truong, S. Bray, A. Ashfield, L. Baker, P. Quinlan, L. Wu, J. Bourdon
Journal: Journal of Clinical Oncology (2007)

10505 Background: p53 is a key gene in the development of breast cancer and response to therapy. Nine splice variants of p53 in breast cancer have been identified, with full length p53, p53beta and p53gamma (both 46kD, C terminal truncated proteins) commonly expressed. This study examined the clinical relevance of splice variants in breast cancer. Methods: Tumors from 248 patients with primary breast cancer were examined for mutation with the Roche p53 mutation chip and p53 isoform expression detected by RT-PCR followed by nested PCR; full clinical and pathological data included median follow up of 6.4 years. Results: p53 mutation, identified in 65/248 (26%) cancers, was significantly associated by Chi square test with shorter survival (p=0.001), histological grade 3 (p&lt;0.001) and estrogen receptor (ER) negative cancers (p&lt;0.001), as expected. Expression of p53 beta or p53 gamma mRNA was associated with p53 mutation (p=0.002, Fisher's exact test). Intriguingly, the patient groups with a mutant p53 cancer but expressing p53 gamma or p53 beta or both isoforms had survival curves comparable to patients with cancer containing wild type p53. Similarly, p53 gamma or p53 beta was associated with ER negative cancers (Chi square; p&lt;0.001), but the group of ER negative tumors expressing p53 gamma or p53 beta had improved survival similar to ER positive cancers. Patients with p53 mutant, p53 beta negative and ER negative cancers comprised half of those who died within 3 years of diagnosis. Conclusions: p53 beta or p53 gamma isoform expression in breast cancer is associated with better prognosis and may moderate disease behaviour even in mutant p53 and ER negative cancers. Manipulation of p53 isoforms in breast cancer may thus offer therapeutic potential. No significant financial relationships to disclose.
Brief Communication : Suppression of Spontaneous In Vitro Transformation of Autologous Leukocytes by Plasma From Convalescent and Postconvalescent Infectious Mononucleosis Patients
Authors: R. Shihman Chang, Celsa A. Spina
Journal: JNCI Journal of the National Cancer Institute (1975)

All 14 plasma samples from 13 convalescent and postconvalescent infectious mononucleosis (IM) patients suppressed the spontaneous in vitro transformation of autologous leukocytes. In contrast, only 2 of 8 plasma samples from patients with acute IM suppressed this transformation. All 7 patients whose blood was tested both in the acute and convalescent or postconvalescent phases of IM showed either a conversion in transformation suppression status from negative to positive or an increase in the strength of transformation suppression. Thus recovery from IM appeared to be associated with the ability of plasma to suppress the in vitro spontaneous transformation of autologous leukocytes.
Abstract 13236: Low Body Weight is Significantly Associated with the Incidence of Stroke in Atrial Fibrillation Patients
Authors: Yasuhiro Hamatani, Hisashi Ogawa, Moritake Iguchi, Yugo Yamashita, Masahiro Esato, Yeong-Hwa Chun, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe, Masaharu Akao
Journal: Circulation (2014)

Introduction:  Atrial fibrillation (AF) increases the risk of stroke. Oral anticoagulants (OAC) are effective for the prevention of stroke, but bleeding complications are more often observed in patients with low body weight. The Japanese patients with AF are generally small and lean, and data regarding those with low body weight (≤50 kg) are very limited.   Methods:  The Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Japan. We aimed to enroll all of the AF patients in Fushimi-ku. One-year follow-up was completed in 3,189 patients, and body weight data was available in 2,842 patients. We compared the backgrounds and incidences of clinical events during one-year follow-up between those with low body weight ≤50 kg (LBW) and those without it (non-LBW).   Results:  Patients with LBW accounted for 26.7% (759 patients) of all the patients. LBW group was more often female (LBW 77.9% vs. non-LBW 25.9%; p   Conclusions:  Many of Japanese AF patients have low body weight. They generally have high risk profile for stroke, and indeed showed higher incidence of stroke during one-year follow-up, whereas that of major bleeding was not particularly high.
A single-institution, multidisciplinary approach to primary localized chest wall sarcomas
Authors: F. Duffaud, C. Doddoli, L. Digue, C. Mercier, C. Bouvier, F. Volot, R. Favre
Journal: Journal of Clinical Oncology (2005)

9054 Background: Primary sarcomas involving the chest wall are rare and data concerning treatment and results are sparse. Methods: We reviewed our experience with these sarcomas by using a multidisciplinary approach. A 12 year retrospective study identified 17 adult patients referred to our centre with localized primary bony or softy tissue sarcomas of the chest wall. Median age was 42 years (17–67). The male/female ratio was 3.5:1.Presenting complaints were swelling, pain or both. Tumor location were the rib (n=7) and clavicle (n=2) for bony tumors and posterior chest wall for softy tissue tumors (n=8). Histological types included: Ewing sarcomas (n=5), osteosarcomas (n=2), chondrosarcomas (n=4), malignant fibrous histiocytomas (n=2), and other types (n=4). Results: Twelve patients underwent up-front “en bloc” resections. Five patients (pts) underwent initial biopsy followed by resection. Surgical resections were microscopically complete (R0) for 9 pts, microscopically incomplete (R1) for 7 and macroscopically incomplete (R2) for one. Associated therapies were: radiotherapy for 10 pts (6/8 pts with incomplete resection, 4/9 with complete resection) and chemotherapy (pre-operatively for 5 pts, post-operatively for 13). Thirteen pts (76.5%) achieved adequate local tumor control. Seven pts (41.2%) developed local recurrence (LR) but 2 developed both RL + metastases and 3 developed metastases only. The incidence rate of LR was 23% (3/13 pts) in the adequate local control group and 100% in the local treatment failure group. Median follow-up was 38 months (6–168) and revealed 8 deaths. The 5-year overall survival (OS) and disease-free survival (DFS) rates were 56% and 44%. Histology type and the pattern of first relapse were the most significant predictors of OS (p= 0.04; p=0.03). Patients (n=7) with a LR alone (43% alive at 60 months) had a significantly better survival than those with metastases (no patient alive at 36 months). Adequate local control was the major predictor of DFS (p= 0.01). Conclusion: Chest wall sarcomas are rare and require a combined aggressive multidisciplinary approach. The achievement of tumor local control is a critical step in their treatment process. No significant financial relationships to disclose.
Abstract 9855: Presence of J-waves or Slurs in Chest Pain Patients Predicts Higher Mortality in those Diagnosed as Acute Myocardial Infarction
Authors: Roger Abacherli, Raphael Twerenbold, Tobias Reichlin, Hans-Jakob Schmid, Vic Frolicher, Stefan Osswald, Christian Muller
Journal: Circulation (2013)

BACKGROUND: Although early repolarization is known as a benign, J-waves or slurs on the R wave downslope have recently been associated with sudden cardiac death. We investigated the presence and pr...
Imatinib mesylate with weekly paclitaxel, a feasible regimen for treatment of recurrent epithelial ovarian cancer (rEOC).
Authors: L. Borgato, T. Safra, B. Levinson, J. Pothuri, J. Hope, J. Curtin, E. Andreopoulou, F. Muggia
Journal: Journal of Clinical Oncology (2010)

e15535 Background: Treatment of rEOC patients with weekly paclitaxel has 20-30% response rate (RR). Imatinib mesylate (imatinib, Gleevec), a potent PDGF/PDGF-R tyrosine kinase inhibitor, affects tumor stroma and blood vessels, hypothesized to be specifically active in EOC due to enriched PDGF/PDGF-R expression in ovarian tumor cells and tumor-associated endothelial cells (Apte et al, Gyn.Onc., 2004). We sought to potentiate paclitaxel activity by combining it with Imatinib mesylate. Methods: rEOC patients previously treated with platinum/paclitaxel but no more than 2 additional regimens were enrolled into an IRB-approved protocol. Paclitaxel 80 mg/m2 day 3, 10, 17 every 28 days and oral imatinib 300 mg AM and PM days 1-4, 8-11, and 13-18 (adopted from Bahrani et al, ASCO 2004) were given. Not allowed were major CYP450 substrates. In this, one stage phase II study, the primary objective was to improve RR (CR+PR) from 19% to 25%. A sample size of 50 patients would achieve 80% power to detect an increase of 18% in the rate of survivors without progression (secondary objective) at 12 w by adding Imatinib to paclitaxel. Response by RECIST criteria and CA125 (Rustin's) were assessed at baseline and every 12 w (CA125 at week 4 as well). NCI Common Toxicity Criteria v 2.0 grades were used. Results: From May 2007 to July 2009, 14 patients with rEOC, median age 58 (47-76), and PS 0-1 were enrolled: only 12 were evaluable since 2 were never treated, platinum-free intervals < 6 m in 4 and ≥ 6 m in 10. Only 4 had grade 3 events: 1 diarrhea, 1 edema, 2 neutropenias; grade 2 events: 4 nausea, 2 fatigue; grade 1: 7 neuropathy, 1 edema. Partial responses by RECIST in 2 and by CA125 in 2 were defined in 4 patients (2/4 platinum resistant). Progression-free survival was > 6 m in 4 (2 > 1 y). With robust safety information based on median follow up of 12.7 m (2.6-27.6) - a joint decision (with sponsor Novartis) was made to close the study, partially since efficacy relative to paclitaxel requires outcome measures beyond RR. Conclusions: This weekly paclitaxel regimen with intermittent imatinib is feasible for long-term administration in rEOC patients. A randomized study is required to assess imatinib's contribution to weekly paclitaxel treatment. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson
Chemoprevention with enzastaurin: First-year results
Authors: J. E. Gray, S. Altiok, M. Alexandrow, F. Walsh, M. Tockman, G. Bepler
Journal: Journal of Clinical Oncology (2009)

1520 Background: Chemoprevention is crucial for reducing lung cancer mortality. The implementation and conduct of such trials is complex. We evaluated accrual in an ongoing trial. Methods: We are conducting a study evaluating if enzastaurin, a protein kinase C beta inhibitor, decreases the Ki-67 labeling index in bronchial epithelium after 6 months of therapy compared to placebo. Eligibility includes age 45 or younger, smoking 30 or fewer packs per year, quit for less than one 1 year, and bronchial meta/dysplasia. Results: Two-thousand eight hundred and nine potential subjects were selected from our database. Between December 2007 and November 2009, 1,242 were invited to participate by an introductory letter and at least 3 attempted telephone contacts. Phone contact was established with 621 (50%) subjects. 245 (39%) declined, 238 (38%) were ineligible, and 138 (22%) were interested in trial participation. At the first face-to-face visit, 57 out of 138 (38%) were eligible, 71 (51%) had not quit smoking for less than 1 year, one (1%) was ineligible for other reasons, and nine (7%) visits are pending. All 57 eligible subjects had an induced sputum exam: 36 had atypia, 19 were normal, and two were inadequate. Bronchoscopies with white light and laser-induced fluorescence and three or fewer biopsies have been done on 22 subjects (4 pending, 4 withdrew, 6 ineligible for bronch). Three had normal histology at all sites, 16 had metaplasia, and two had dysplasia in at least one site (84% abnormal bronchial histology rate, 1 pending). No occult cancers were identified. Conclusions: Of 1,242 preselected potential participants, 11% presented for a first face-to-face visit, 4.6% were eligible after a sputum exam, and 2.4% were fully eligible for randomization. Thus, to reach the accrual goal of 186 patients, we estimate that we will need to contact 7,700 subjects. During our 12-month period, we accessed 1,242 patients with 2.0 FTE for study coordinators (not including the pathologist, bronchoscopist, and laboratory personnel). Our expectation had been to accomplish accrual over a period of 42 months from a pool of 2,809 existing putative patients. Unless our eligibility rate of 2.4% increases, further sources of patients must be identified to accomplish our accrual goal. No significant financial relationships to disclose.
The diagnostic value of serum β-CTX and urinary CTX/CR in lung cancer with bone metastasis
Authors: Mathew, Haque, Woothipoom, 李君（译）
Journal: BMJ (2007)

The study included 24 patients of lung cancer with bone metastasis, 26 patients of lung cancer without bone metastasis and 27 healthy controls. The serum levels of β-crosslaps of type Ⅰ collagen (β-CTX), M-MID and urinary β-CTX/creatinine (CTX/CR) were measured by ELISA. Results showed that the serum levels of β-CTX and urinary CTX/CR in lung cancer patients with bone metastasis were significantly higher than those without bone metastasis (P ＜ 0. 01 ). The findings suggest that the measurement of serum β-CTX and urinary CTX/CR may indicate bone metastasis in lung cancer.

Key words: 
Lung neoplasms ;  Neoplasm metastasis ;  β-crosslaps of type Ⅰ collagen ;
Abstract 17077: The Impact of Ethyl Icosapentate Therapy on Coronary Fibrous-Cap Thickness in Acute Coronary Syndrome Patients without Hyperlipidemia: Assesment by Optical Coherence Tomography Study
Authors: Takashi Yamano, Teruaki Wada, Masahiro Takahata, Shingo Ota, Yuichi Ozaki, Kunihiro Shimamura, Yasutudu Shiono, Makoto Orii, kohei Ishibashi, Takashi Tanimoto, Yasushi Ino, Tomoyuki Yamaguchi, kumiko Hirata, Takashi kubo, Toshio Imanishi, Takashi Akasaka
Journal: Circulation (2012)

BACKGROUND: It plays important roles to predict vulnerable plaques in patients with acute coronary syndrome (ACS) because the vulnerability of coronary plaques has been relevant to the pathogenesis...